Moyong reveals less demand for COVID vaccines No matter how many needles you inject, it won’t prevent you from sticking. But it helps reduce the risk of serious illness. As for the new model that Thailand has donated, I’m not sure that it can be used.
Issara News Agency (www.isranews.org) reported that on March 3, 2023, Prof. Yong Phuwarawan, M.D., Royal Institute and Head of the Center of Excellence in Clinical Virology Department of Pediatrics Faculty of Medicine Chulalongkorn University posted on Facebook Yong Poovorawan indicating the reduced demand for the COVID-19 vaccine as follows.
In the first year of vaccination Everyone is very competitive. As more vaccines become available, mRNA is called the god vaccine. over time It can be seen that all vaccines are equally effective.
to the present No matter how many doses of vaccination, it can’t prevent infection, but it can only reduce the severity of the disease.
Today, most of the world’s population has been infected, probably 5 billion, with even Thailand likely to have infected more than 50 million.
Vaccine-induced immunity and infection, especially late infection that is more strain-matched calm the disease tendency
The vaccines that are still in stock now are over demand. As a result, a large number of expired vaccines were destroyed. and expedite the release of vaccines in stock by donating Vaccine companies stopped production. will only be produced when orders come in and the order must be purchased in bulk and mRNA-based vaccines have a shorter lifespan.
The vaccine we have donated Even if it’s 2 species, I’m not confident that it can be used all.
Companies will not develop more new species Because the virus is constantly changing. Variation in vaccine strains It didn’t have much effect.
In addition, new strains of vaccines using genetic processes in mRNA and vector viruses require codon modification, therefore requiring more experiments. before being used It’s not like the flu vaccine. infectious Just change the seed species according to the World Health Organization. can develop a vaccine within 6 months